Charles Schwab Investment Management Inc Oncorus, Inc. Transaction History

Charles Schwab Investment Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.04 - $1.86 $45,026 - $80,528	-43,295 Closed	0 $0
Q3 2021 Nov 16, 2021	SELL	$9.29 - $14.27 $373,439 - $573,625	-40,198 Reduced 48.15%	43,295 $405,000
Q2 2021 Aug 16, 2021	BUY	$13.3 - $17.3 $338,844 - $440,752	25,477 Added 43.91%	83,493 $1.15 Million
Q1 2021 May 17, 2021	BUY	$11.89 - $35.55 $226,659 - $677,689	19,063 Added 48.94%	58,016 $808,000
Q4 2020 Feb 16, 2021	BUY	$15.0 - $35.15 $584,295 - $1.37 Million	38,953 New	38,953 $1.26 Million

Ticker ONCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,973,100
Description
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.